Anti-inflammatory and metabolic effects of candesartan in hypertensive patients
- 24 October 2005
- journal article
- clinical trial
- Published by Elsevier in International Journal of Cardiology
- Vol. 108 (1) , 96-100
- https://doi.org/10.1016/j.ijcard.2005.07.040
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With MicroinflammationCirculation, 2004
- Diabetes and Vascular DiseaseCirculation, 2003
- Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endotheliumCurrent Diabetes Reports, 2003
- Minireview: Adiposity, Inflammation, and AtherogenesisEndocrinology, 2003
- Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyJournal Of Hypertension, 2002
- Prognostic Significance of Endothelial Dysfunction in Hypertensive PatientsCirculation, 2001
- Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesionsThe American Journal of Cardiology, 2001
- Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stabilityCardiovascular Research, 2000
- Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.Journal of Clinical Investigation, 1997
- Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40–CD40 ligand signaling in atherosclerosisProceedings of the National Academy of Sciences, 1997